eCite Digital Repository
Pharmacoeconomic evidence of bosentan for pulmonary arterial hypertension
Citation
Strange, G and Keogh, A and Dalton, B and Gabbay, E, Pharmacoeconomic evidence of bosentan for pulmonary arterial hypertension, Expert Review of Pharmacoeconomics & Outcomes Research, 11, (3) pp. 253-263. ISSN 1473-7167 (2011) [Refereed Article]
![]() | PDF Not available 368Kb |
Copyright Statement
Copyright 2011 Expert Reviews Ltd.
Abstract
In this article, we review randomized controlled trials, open-label trials and pharmacoeconomic
models of bosentan for the management of patients with pulmonary arterial hypertension.
Bosentan consistently improves WHO functional class and quality of life, slows clinical worsening
and is associated with improved survival compared with historical treatment. Although headto-
head trials are scarce, data directly comparing bosentan with sildenafil indicate no clinically
significant differences between treatments as measured by the 6-min walk distance alone.
Compared with historical care, bosentan treatment, over a 15–30-year period, increases the
number of quality-adjusted life years (3.49 years). Economic modeling suggests that the
cost–effectiveness of bosentan is similar to that of ambrisentan (US$43,725–57,778 per qualityadjusted
life year), not as cost effective as sildenafil (at 20 mg three-times daily) and more cost
effective than iloprost. More randomized controlled trials of longer duration are required to
confirm the results from these economic models.
Item Details
Item Type: | Refereed Article |
---|---|
Keywords: | cost-effectiveness; endothelin receptor antagonists; incremental cost-effectiveness ratio; phosphodiesterase inhibitors; pulmonary arterial hypertension; quality-adjusted life years |
Research Division: | Biomedical and Clinical Sciences |
Research Group: | Pharmacology and pharmaceutical sciences |
Research Field: | Clinical pharmacy and pharmacy practice |
Objective Division: | Health |
Objective Group: | Evaluation of health and support services |
Objective Field: | Evaluation of health outcomes |
UTAS Author: | Dalton, B (Mr Brad Dalton) |
ID Code: | 78015 |
Year Published: | 2011 |
Web of Science® Times Cited: | 5 |
Deposited By: | Health Sciences A |
Deposited On: | 2012-06-12 |
Last Modified: | 2017-11-02 |
Downloads: | 0 |
Repository Staff Only: item control page